FTSE MIB
33.733,71 +424,94 (+1,28%) Dow Jones
39.150,33 +15,53 (+0,04%) Nasdaq
17.689,36 -32,24 (-0,18%) Nikkei 225
38.804,65 +208,18 (+0,54%) Petrolio
80,93 +0,20 (+0,25%) Bitcoin EUR
56.798,90 -3.068,68 (-5,13%)
PRME Jun 2024 10.000 put
| Chiusura precedente | 2,0000 |
| Aperto | N/D |
| Denaro | 2,0000 |
| Domanda | 6,0000 |
| Prezzo d'esercizio | 10,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 2,0000 - 2,0000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswirePrime Medicine to Present at Upcoming Investor Conferences
Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences: BMO Biopharma Virtual Spotlight Series: Latest Advances in Genome / Epigenome Editing: Fireside chat on Tuesday, September 26, 2023, at 10
- GlobeNewswire
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio’s shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBR
